



Botulinum toxin dosing in arm muscles: contextual factors

Dirk Dressler¹ · Bruno Kopp² · Fereshte Adib Saberi¹

Received: 8 September 2020 / Accepted: 14 January 2021
© The Author(s) 2021

Abstract

Botulinum toxin (BT) has been successfully used for many years to treat various muscle hyperactivity disorders including dystonia and spasticity. Its dosing is guided by dosing tables describing target muscles and dose ranges. To refine the BT dosing, we wanted to analyse how contextual factors may influence the injector's final dosing decision.

In a retrospective review of real-life data of 1170 BT treatments, we studied the influence of various contextual factors on the BT doses in 21 arm muscles of 252 patients receiving BT therapy for different muscle hyperactivity disorders.

We found that BT arm doses are significantly higher in treatment of spasticity than in treatment of dystonia. We also found that spontaneous arm dystonia requires higher BT doses in a proximal application pattern, whereas task specific writer's cramp requires considerably reduced BT doses with a distal application pattern. Injections of non-arm muscles influence the BT dosing in arm muscles only marginally.

Our study demonstrates that BT dosing does not only depend on the particularities of the individual target muscle injected, such as its volume and its static or phasic function. BT dosing and its application pattern rather depend on additional contextual factors such as the aetiology and pathophysiology of the muscle hyperactivity treated. These contextual factors need to be included in dosing tables and may improve the outcome of BT therapy.

Keywords Botulinum toxin · Therapy · Dystonia · Spasticity · Writer's cramp · Dosing tables · Contextual factors

Introduction

Botulinum toxin (BT) has been successfully used for many years to treat various muscle hyperactivity disorders including dystonia and spasticity. As BT acts locally it has to be injected in appropriate doses into the relevant muscles. This dosing is guided by dosing tables so far only describing dose ranges irrespective of specifying contextual factors. To refine BT dosing we wanted to analyse how contextual factors including the aetiology and pathophysiology of the treated condition and additional BT application elsewhere in the body may influence the injector's final dosing decision.

Methods

Design

The study is a non-interventional retrospective review of treatment data of patients receiving routine BT therapy of arm muscles. Contextual factors potentially influencing BT arm muscle dosing included (1) the muscle hyperactivity's aetiology (dystonia vs spasticity), (2) its pathophysiology (arm dystonia vs writer's cramp) and (3) additional BT application (BT application for isolated arm spasticity vs BT application for hemispasticity vs BT application for tetraspasticity).

Data base

Treatment data originated from the computerised BT therapy data base of the Movement Disorders Section, Department of Neurology, Hannover Medical School, Hannover, Germany. This institution was founded 12 years ago by one of the authors (DD) and is specialised in BT therapy. Currently, its annual BT usage is in excess of 20,000 100MU

✉ Dirk Dressler
dressler.dirk@mh-hannover.de

¹ Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany

² Department of Neurology, Hannover Medical School, Hannover, Germany

vial equivalents of onabotulinumtoxinA (ONA, Botox®, Allergan, Dublin, Ireland) and incobotulinumtoxinA (INCO, Xeomin®, Merz Pharmaceuticals, Frankfurt/M, Germany). Data used for this study are real-life data routinely collected at this institution. For each indication, treatment data were consecutively collected until pre-set numbers were reached.

Treatment algorithms applied

BT therapy is based on the algorithms developed during the last 33 years by one of the authors (DD) and his team. This reference centre is able to perform BT therapy with a minimum of economic and legal restrictions thus being able to exploit the full benefit of this therapy. For all patients treated BT therapy is free of costs. Regulatory recommendations on target muscle selection and dosing, total doses, inter-injection intervals and contraindications are modified wherever necessary. Permission to perform quantitative and qualitative off-label use was applied for and generally granted. Total doses of up to INCO 1500MU and INCO inter-injection intervals down to 6 weeks may be applied wherever necessary.

BT therapy

The standard reconstitution for ONA 100MU vials and INCO 100MU vials uses 2.5 ml 0.9% NaCl/H₂O. The standard volume per injection site is 0.5 ml (20MU); hence the number of injection sites is mainly determined by the BT doses applied to each target muscle.

Patients

The study was performed on 80 patients with unilateral arm spasticity, 83 patients with hemispasticity, 29 patients with tetraspasticity, 50 patients with writer's cramp and 10 patients with arm dystonia. Arm dystonia described patients with spontaneous, non-action induced or non-task specific arm dystonia. Writer's cramp describes patients with task specific arm dystonia triggered by writing.

Statistics

The significance level was set to $\alpha = 0.05$. As 23/29 patients with tetraspasticity showed bilateral arm involvement, the statistical analysis was based on the arm on the more severely affected and, thus, higher dosed side. ONA and INCO doses were converted into equivalent mouse units (MU-E) based on a conversion ratio of 1:1 (Dressler 2009, 2010; Dressler et al. 2012, 2014b, 2018).

Results

Patients

Altogether 1170 BT arm muscle treatments in 21 arm muscles of 252 patients were studied. As shown in Table 1, patients with spasticity (arm spasticity, hemispasticity and tetraspasticity) show a male preponderance ($\chi^2 = 10.08$, $p = 0.001$), while patients with dystonia (writer's cramp and arm dystonia) do not show a preponderance ($\chi^2 = 0.276$, $p = 0.606$). There was no difference detectable in patient age with spasticity and dystonia ($t = 1.024$, $p = 0.307$).

Arm muscle dosing under the contextual factor 'additional BT application'

Table 2 shows BT therapy of 1002 arm muscle treatments in 18 different arm muscles of 192 patients when isolated arm spasticity was treated and when hemispasticity and tetraspasticity were treated. The BT arm dose per patient was 388.3 ± 67.8 MU-E in isolated arm spasticity, 322.2 ± 141.9 MU-E in hemispasticity and 310.7 ± 161.6 MU-E in tetraspasticity. Therefore, it was lower when isolated arm spasticity rather than hemispasticity and tetraspasticity were treated, whereas there was no difference when hemispasticity rather than tetraspasticity was treated (overall group difference, $F(df=2, 189) = 4.648$, $p = 0.011$; post hoc tests: arm spasticity vs hemispasticity, $t = 2.709$, $p_{Holm} = 0.022$; arm spasticity vs tetraspasticity, $t = 2.298$, $p_{Holm} = 0.045$; hemispasticity vs tetraspasticity, $t = 0.342$, $p_{Holm} = 0.733$). The number of target muscles treated per patient was 6.5 ± 2.7 in isolated arm spasticity, 5.3 ± 2.4 in hemispasticity and 5.0 ± 2.0 in tetraspasticity. Therefore, it was also smaller when isolated arm spasticity rather than hemispasticity and tetraspasticity were treated, whereas there was no difference when hemispasticity rather than tetraspasticity was treated (overall group difference, $F(df=2, 189) = 6.252$, $p = 0.002$; post hoc tests: arm spasticity vs hemispasticity, $t = 3.137$, $p = 0.006$; arm spasticity vs

Table 1 Patient demographics

Indication	Patient numbers [n]	Patient age (M ± SD) [years]	Patient sex [%]	
			Male	Female
Arm spasticity	80	59.1 ± 14.5	65	35
Hemispasticity	83	58.4 ± 14.7	59	41
Tetraspasticity	29	43.8 ± 16.7	59	41
Writer's cramp	50	57.4 ± 13.5	48	52
Arm dystonia	10	37.2 ± 19.7	40	60

M ± SD mean ± standard deviation

Table 2 Botulinum toxin therapy of arm muscles under the contextual factor ‘additional botulinum toxin therapy’

Indication	BTT for AS	BTT for HS	BTT for TS	Significance	BTT for ALLS
Number of patients treated [n]	80	83	29	n/a	192
Number of arm muscles treated [n]	518	436	146	n/a	1002
BT arm dose per patient (M ± SD) [MU-E]	388.3 ± 67.8	322.2 ± 141.9	310.7 ± 161.6	AS vs HS: * AS vs TS: * HS vs TS: ns	378.3 ± 186.3
Number of arm muscles treated per patient (M ± SD) [n]	6.5 ± 2.7	5.3 ± 2.4	5.0 ± 2.0	AS vs HS: * AS vs TS: * HS vs TS: ns	6.3 ± 3.0

n/a not applicable, ns not significant, M ± SD mean ± standard deviation, BT botulinum toxin, BTT botulinum toxin therapy, MU-E equivalent mouse unit, AS arm spasticity, HS hemispasticity, TS tetraspasticity, ALLS all spasticity

*Significant

tetraspasticity, $t = 2.673$, $p_{Holm} = 0.016$; hemispasticity vs tetraspasticity, $t = 0.407$, $p_{Holm} = 0.684$).

Arm muscle dosing under the contextual factor ‘aetiology’

Table 3 shows the BT therapy of 1002 BT arm muscle treatments in 18 different arm muscles of 192 patients with spasticity (arm spasticity, hemispasticity, tetraspasticity), of 128 BT arm muscle treatments in 12 different arm muscles of 50 patients with writer’s cramp and of 40 BT arm muscle treatments in 8 different arm muscles of 10 patients with arm dystonia. The BT arm dose per patient in writer’s cramp was 70.3 ± 55.3 MU-E, in arm dystonia 196.0 ± 150.8 MU-E and in spasticity 378.3 ± 186.3 MU-E. With this, the BT arm dose per patient in writer’s cramp was 19% of the BT arm dose per patient in spasticity and 36% of the one in arm dystonia. Group differences of BT arm dose per patient reached statistical significance (overall group difference, $F (df = 2, 249) = 75.83$, $p < 0.001$; post hoc tests: spasticity vs dystonia, $t = 3.254$, $p_{Holm} = 0.003$; spasticity vs writer’s

cramp, $t = 12.145$, $p_{Holm} < 0.001$; dystonia vs writer’s cramp, $t = 2.52$, $p_{Holm} = 0.012$).

The number of arm target muscles per patient was 2.5 ± 1.5 in writer’s cramp, 4.4 ± 2.2 in arm dystonia and 5.7 ± 2.6 in spasticity. Group differences of BT number of target muscles per patient reached statistical significance (overall group difference, $F (df = 2, 249) = 36.35$, $p < 0.001$; post hoc tests: spasticity vs dystonia, $t = 1.73$, $p_{Holm} = 0.085$; spasticity vs writer’s cramp, $t = 8.481$, $p_{Holm} < 0.001$; dystonia vs writer’s cramp, $t = 2.267$, $p_{Holm} = 0.048$).

Arm muscle dosing under the contextual factor ‘pathophysiology’

Table 4 and Fig. 1 show the distribution patterns of BT arm doses in patients with spasticity, arm dystonia and writer’s cramps. In the shoulder muscles (M. pectoralis, M. teres major, M. latissimus dorsi, M. deltoideus) BT doses were 60.3 ± 2.1 MU-E in spasticity, 50.5 ± 11.9 MU-E in arm dystonia and 62.5 ± 53.0 MU-E in writer’s cramp. The M. deltoideus was occasionally used in writer’s cramp to reduce shoulder abduction. In the elbow muscles (M.

Table 3 Botulinum toxin therapy of arm muscles under the contextual factor ‘aetiology’

Indication	All Spasticity	Writer’s cramp	Arm dystonia	Significance
Number of patients treated [n]	192	50	10	n/a
Number of arm muscles treated [n]	1002	128	40	n/a
BT arm dose per patient (M ± SD) [MU-E]	378.3 ± 186.3	70.3 ± 55.3	196.0 ± 150.8	ALLS vs WC: * ALLS vs AD: * WC vs AD: *
Number of arm muscles treated per patient (M ± SD) [n]	6.3 ± 3.0	2.5 ± 1.5	4.4 ± 2.2	ALLS vs WC: * ALLS vs AD: ns WC vs AD: *


n/a not applicable, ns not significant, M ± SD mean ± standard deviation, BT botulinum toxin, MU-E equivalent mouse unit, ALLS all spasticity, WC writer’s cramp, AD arm dystonia

*Significant

Table 4 Botulinum toxin therapy of arm muscles under the contextual factor ‘pathophysiology’

Muscle groups	Spasticity <i>n</i> = 194	Arm dystonia <i>n</i> = 40	Writer’s cramp <i>n</i> = 128
Shoulder muscles (<i>M</i> ± <i>SD</i>) [MU-E]	<i>n</i> = 194 60.3 ± 2.1	<i>n</i> = 18 50.5 ± 11.9	<i>n</i> = 2 62.5 ± 53.0
Elbow muscles (<i>M</i> ± <i>SD</i>) [MU-E]	<i>n</i> = 261 51.1 ± 8.2	<i>n</i> = 13 41.9 ± 8.7	<i>n</i> = 1 30.0 ± 0
Wrist muscles (<i>M</i> ± <i>SD</i>) [MU-E]	<i>n</i> = 160 54.5 ± 5.4	<i>n</i> = 9 40 ± 0	<i>n</i> = 59 31.2 ± 12.4
Forearm/hand muscles (<i>M</i> ± <i>SD</i>) [MU-E]	<i>n</i> = 387 59.4 ± 20.1		<i>n</i> = 66 24.4 ± 12.6

M ± *SD* mean ± standard deviation, *N* number, *MU-E* equivalent mouse units

**Fig. 1** Distribution pattern of botulinum toxin doses in patients with spasticity, arm dystonia and writer’s cramps

biceps brachii, M. brachialis, M. brachioradialis and M. triceps brachii) BT doses were 51.5 ± 8.2 MU-E in spasticity, 41.9 ± 8.7 MU-E in arm dystonia and 30 MU-E in writer’s cramp. The elbow muscles were very rarely used in the treatment of writer’s cramps. In the wrist muscles (M. flexor carpi ulnaris, M. flexor carpi radialis, M. extensor carpi ulnaris and M. extensor carpi radialis) the BT doses were 54.5 ± 5.4 MU-E in spasticity, 40.0 ± 0 MU-E in arm dystonia and 31.2 ± 12.4 MU-E in writer’s cramp. The wrist muscles were only rarely used in the treatment of arm dystonia. In forearm muscles and hand muscles (M. pronator teres, M. flexor digitorum superficialis, M. flexor digitorum profundus, M. extensor digitorum, M. flexor pollicis brevis, Mm. lumbricales, intrinsic thumb muscles, M. extensor indicis, M. flexor indicis and M. extensor pollicis) the BT dose was 59.4 ± 20.1 MU-E in spasticity and 24.4 ± 12.6 MU-E in writer’s cramp. None of these muscles were targeted in arm dystonia.

Discussion

Dosing tables for BT therapy are describing BT doses for the target muscles treated. In their most basic form they give a typical dose, in more elaborate forms they are giving dose ranges. The most recent dosing table is—for the first time—based on an statistical analysis of real-life treatment data (Dressler 2018). It shows typical doses (mean doses), dose variabilities (standard deviations) and dosing limits (minimum, maximum). Also for the first time, it distinguishes target muscle doses according to specific aetiologies of the muscle hyperactivity treated, i.e. spasticity and dystonia. Still, there is a gap to find the final BT dose applied in individual patients. We wanted to fill this gap by studying additional contextual factors influencing the final dosing decision. For this we focussed on BT therapy of arm muscles and studied the dosing effects of various contextual factors.

Contextual factor ‘additional BT therapy’

Although arm muscle doses and number of arm target muscles are reduced when more wide-spread spasticity is treated, this effect is mild and partially non-significant. This may reflect recently introduced changes in treatment algorithms allowing BT high dose therapies in total doses of up to 1250 MU of incobotulinumtoxinA (Dressler et al. 2014a; Wissel et al. 2017) thus lifting restrictions of BT total doses hitherto applied.

Contextual factor ‘aetiology’

We found that BT arm doses are significantly higher in treatment of spasticity than in treatment of dystonia. Especially treatment of writer’s cramp requires considerably reduced BT dosing. Similar effects are seen in the number of target muscles treated. Reasons for that may include the following: Spasticity includes by definition (Dressler et al. 2017) variable degrees of paresis. When this paresis is substantial and spasticity is strong, robust BT doses may be given without concerns of additional paretic side effects. In contrary, dystonia does not include paresis and concerns about paretic side effects often arise, especially in writer’s cramp.

Contextual factor ‘pathophysiology’

We found that spontaneous dystonia (‘arm dystonia’) and task specific dystonia (‘writer’s cramp’) require a much different BT therapy. Whereas BT therapy of arm dystonia requires a BT distribution patterns with a strong proximal

preponderance, the BT distribution pattern for writer's cramp has a strong distal preponderance. This may reflect the typical temporal and geographic expansion of arm dystonia often developing from cervical dystonia. Within this special distribution pattern writer's cramp requires considerably reduced BT doses. This reflects the narrow therapeutic window of distal arm muscles (especially when they are extensors) (Dressler 2000) and the extraordinary complex functionality of finger muscles.

Our study demonstrates that BT dosing does not only depend on the particularities of the individual target muscle injected, such as its volume and its static or phasic function.

BT dosing and its application pattern rather depend on additional contextual factors such as the aetiology and pathophysiology of the muscle hyperactivity treated. BT dosing and its application pattern rather depends on additional contextual factors such as the aetiology and pathophysiology of the muscle hyperactivity treated. These contextual factors need to be included in dosing tables and may improve the outcome of BT therapy. Additional studies into other contextual factors and into other body regions may further refine BT therapy.

Funding Open Access funding enabled and organized by Projekt DEAL.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Dressler D (2000) Botulinum Toxin Therapy. Thieme, Stuttgart
- Dressler D (2009) Routine use of Xeomin® in patients pre-treated with Botox®. *Eur J Neurol* 16(Suppl 2):2–5
- Dressler D (2010) Comparing Botox® and Xeomin® for the treatment of axillar hyperhidrosis. *J Neural Transm* 117:317–319
- Dressler D (2018) Dosing Schemes for Botulinum Toxin Therapy of Dystonia. In: Dressler D, Altenmüller E, Krauss JK (eds) *Treatment of Dystonia*. Cambridge University Press, Cambridge
- Dressler D, Mander G, Fink K (2012) Measuring the potency labelling of onabotulinumtoxinA (Botox®) and Xeomin® in an LD50 assay. *J Neural Transm* 119:13–15
- Dressler D, Adib Saberi F, Kollewe K, Schrader C (2014a) Safety aspects of incobotulinumtoxinA high dose therapy. *J Neural Transm* 122:327–333
- Dressler D, Tacik P, Adib Saberi F (2014b) Botulinum toxin therapy of cervical dystonia: Comparing Botox® and Xeomin®. *J Neural Transm* 121:29–31
- Dressler D, Bhidayasiri R, Bohlega S, Chahidi A, Mo Chung T, Ebke M, Jacinto LJ, Kaji R, Koçer S, Kanovsky P, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sagástegui-Rodríguez JA, Schoenle PW, Shahidi GA, Timerbaeva S, Walter U, Adib Saberi F (2017) Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB - interdisciplinary working group for movement disorders task force. *J Neurol* 264:112–120
- Dressler D, Pan L, Bigalke H (2018) Comparing IncobotulinumtoxinA (Xeomin®) and OnabotulinumtoxinA (Botox®): Identical Potency Labelling in the Hemidiaphragm Assay. *J Neural Transm* 125:1351–1354
- Wissel J, Bensmail D, Ferreira J, Molteni F, Satkunam L, Moraleda S, Rekand T, McGuire J, Scheschonka A, Flatau-Baqué B, Simon O, Dressler D, Simpson DM (2017) Safety and efficacy of incobotulinumtoxinA doses up to 800 U in spasticity: the TOWER study. *Neurology* 88:1321–1328

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com